冠心病患者血清Lp（a）、NEFA水平变化及临床意义

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (446 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objectives To analyze the change and clinical significance of serum lipoprotein a [Lp(a)] and non-esterified fatty acid (NEFA) levels in patients with coronary heart disease (CHD). Methods From May 2016 to January 2019, 143 cases with CHD diagnosed in Chenzhou First People′s Hospital of Hu′nan Province were selected as the study group. According to the lesion branch, they were divided into single branch lesion subgroup (54 cases), double branch lesion subgroup (49 cases) and multi-branch lesion subgroup (40 cases). According to Gensini scores, they were divided into low score subgroup (34 cases), middle score subgroup (47 cases) and high score subgroup (62 cases). And 106 patients who underwent coronary angiography at the same time, with mild stenosis and coronary artery occlusion less than 30% were selected as the control group. Serum Lp(a) and NEFA levels were compared between the two groups. Pearson correlative analysis was used to analysed the correlation between Lp(a), NEFA levels and lesion branch, Gensini scores, the level of Lp(a) and NEFA. Results The serum levels of Lp(a) and NEFA in the study group were higher than those in the control group, and the differences were statistically significant (all P < 0.05). The levels of serum Lp(a) and NEFA in the study group increased with the number of coronary artery lesion branchesand the degree of lesions (P < 0.05). Pearson correlative analysis showed that serum Lp(a) and NEFA levels were positively correlated with Gensini scores (r = 0.482, 0.503, P ＜ 0.05). Serum Lp(a) and NEFA levels were positively correlated with the number of lesions (r = 0.513, 0.472, P ＜ 0.05). The serum Lp(a) in CHD patients was positively correlated with NEFA (r = 0.469, P ＜ 0.05). Conclusion The levels of serum Lp(a) and NEFA in CHD patients are significantly increased, and are positively correlated with the number of lesions and Gensini scores. The detection of Lp(a) and NEFA are of great significance for the clinical diagnosis and treatment of CHD patients.

Key words： Coronary heart disease Lipoprotein a Non-esterified fatty acid

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Mingpeng SHI Tingfeng GUO Zi′an GUO Manrong WANG Zhonghua

Cite this article:

LI Mingpeng SHI Tingfeng GUO Zi′an GUO Manrong WANG Zhonghua. Change and clinical significance of serum Lp(a) and NEFA levels in patients with coronary heart disease[J]. 中国医药导报, 2020, 17(2): 61-64.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I2/61

[1] 张志芳，左建华，肖华，等.栝楼薤白半夏汤加味结合西医常规疗法治疗气滞血瘀型冠心病心绞痛临床研究[J].国际中医中药杂志，2016，38（12）：1076-1079.
[2] Stability Investigators，White HD，Held C，et al. Darapladib for preventing ischemic events in stable coronary heart disease [J]. N Engl J Med，2014，370（18）：1702-1711.
[3] Zewinger S，Kleber ME，Tragante V，et al. Relations between lipoprotein（a）concentrations，LPA genetic variants，and the risk of mortality in patients with established coronary heart disease：a molecular and genetic association study [J]. Lancet Diabetes Endocrinol，2017，5（7）：534-543.
[4] 周力，赵昱，陈晖，等.C反应蛋白和纤维蛋白原与合并结缔组织病的冠心病患者长期预后的相关性研究[J].医学综述，2018，24（13）：2521-2525.
[5] 袁云龙，吴嘉，宋佳希，等.冠心病患者血清游离脂肪酸、氧化脂蛋白（a）与冠状动脉病变程度的关系[J].临床检验杂志，2015，33（2）：99-103.
[6] 薛魁.不同类型冠心病患者血浆游离脂肪酸水平变化及其与病变程度的关系[J].检验医学与临床，2016，13（22）：3171-3172.
[7] Jia G，Whaley-Connell A，Sowers JR. Diabetic cardiomyopathy：a hyperglycaemia-and insulin-resistance-induced heart disease [J]. Diabetologia，2018，61（1）：21-28.
[8] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心血管病预防指南[J].柳州医学，2012，5（4）：263-279.
[9] 吴微，王周哲，张远生.血清脂蛋白a水平与冠心病患者Gensini积分的相关性分析[J].实用心脑肺血管病杂志，2017，25（3）：141-143.
[10] 龚博君，李自成.冠心病患者脂蛋白a与纤维蛋白原及Gensini积分的相关性[J].临床心血管病杂志，2013，29（10）：732-734.
[11] 赵慈余，余细平，夏骏，等.脑卒中高危人群血清游离脂肪酸与颈动脉狭窄的关系研究[J].中华老年心脑血管病杂志，2017，19（1）：9-12.
[12] 韩雅玲.冠心病溶栓与抗栓治疗的现状与思考[J].中华心血管病杂志，2016，44（2）：90-92.
[13] Benjamin EJ，Blaha MJ，Chiuve SE，et al. Heart disease and stroke statistics-2017 update：a report from the American Heart Association [J]. Circulation，2017，135（10）：e146-e603.
[14] 郭志霞，赵兴胜.同型半胱氨酸与冠心病发病机制及相关性研究进展[J].医学综述，2019，25（22）：4477-4482.
[15] Ljungberg J，Holmgren A，Bergdahl IA，et al. Lipoprotein（a）and the apolipoprotein B/A1 ratio independently associate with surgery for aortic stenosis only in patients with concomitant coronary artery disease [J]. J Am Heart Assoc，2017，6（12）：e 007 160.
[16] 梁丽华，孙龙胤，张艳萍.冠心病诊断中脂蛋白a和同型半胱氨酸联合检测的价值探析[J].中国实用医药，2017， 12（32）：38-39.
[17] 董素娟，万书平，杨广龙，等.芝麻素对冠心病大鼠脂代谢、血管内皮功能损伤及VCAM-1水平的影响[J].临床和实验医学杂志，2019，18（12）：1242-1246.
[18] 刘玮.冠心病患者血尿酸及同型半胱氨酸水平与冠状动脉病变程度的关系及意义分析[J].中外医学研究，2018， 16（8）：44-45.
[19] 胡新科，李世敬，胡桃红，等.血浆同型半胱氨酸和尿酸及高敏C反应蛋白与冠状动脉粥样硬化性心脏病的相关性分析[J].中国医药，2019，14（3）：342-345.
[20] 戴雯，黄允，李艳.血清脂蛋白相关磷脂酶A2和游离脂肪酸水平与冠心病患者冠状动脉病变的关系[J].微循环学杂志，2017，27（4）：39-42.
[21] 林育辉，何晓青.游离脂肪酸、同型半胱氨酸和超敏C反应蛋白与冠状动脉病变的相关性[J].广东医学，2016，37（10）：1516-1517.
[22] 钟素，余研，苏晓娟，等.冠心病患者血清visfatin水平与氧化应激及颈动脉粥样硬化的关系[J].中国医药导报，2019，16（29）：68-71.
[23] 陈庆梅，朱成振，刘丽萍，等.冠心病患者血清同型半胱氨酸和血脂水平的检测价值研究[J].中国现代医生，2018，56（34）：9-11.
[24] 刘小永.冠状动脉病变与hs-CRP、FFA和APN的相关性研究[D].昆明：昆明医学院，2010.
[25] Pokrovsky S，Straube R，Afanasieva O，et al. Lp（a）apheresis for the treatment of severe CHD patients with Lp（a） hyperlipidemia [J]. Ther Apher Dial，2010，9（5）：A40.
[26] 温文慧，匡泽民，王绿娅.重新认识脂蛋白（a）促进动脉粥样硬化性心血管疾病的作用[J].临床检验杂志，2018，36（3）：190-192.